PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma

Liangjun Rao, Xiaoyan Wang, Zhen Zong, Zhifeng Chen, Xinchong Shi, Chang Yi, Xiangsong Zhang, Zhiyun Yang, Liangjun Rao, Xiaoyan Wang, Zhen Zong, Zhifeng Chen, Xinchong Shi, Chang Yi, Xiangsong Zhang, Zhiyun Yang

Abstract

The aim of the study was to compare differences between lymphoma and inflammation as indicated by high diffuse uptake of F-fluorodeoxyglucose (F-FDG) in the spleen, liver, and bone marrow without increased F-FDG uptake in the lymph nodes and without enlarged peripheral lymph nodes.Eighteen lymphoma patients and 14 inflammation patients were examined with F-FDG positron emission tomography-computer tomography (PET-CT). All patients displayed high diffuse uptake of F-FDG in the spleen, liver, and bone marrow without increased F-FDG uptake in the lymph nodes and without enlarged peripheral lymph nodes. Our analyses compared the maximum standardized uptake values (SUVmax) of F-FDG uptake ratios between the spleen/liver, the spleen/bone marrow, and the liver/bone marrow and further compared spleen sizes between lymphoma and inflammation patients.Using Student t test, no significant differences were found in the SUVmax ratios of spleen/liver and liver/bone marrow between the lymphoma and inflammation patients (t = 0.853, P = 0.401 > 0.05; t = 1.622, P = 0.115 > 0.05). However, the SUVmax ratio of the spleen/bone marrow of the lymphoma patients was significantly different from that of the inflammation patients (t = 2.426, P = 0.021 < 0.05). The spleen size between the lymphoma and inflammation patients was also significantly different (t = 2.911, P = 0.007 < 0.05).As indicated by F-FDG PET-CT, our study demonstrated that lymphoma and inflammation patients displayed a few differences despite both having high diffuse uptake of F-FDG in the spleen, liver, and bone marrow without enlarged peripheral lymph nodes and without increased F-FDG uptake in lymph nodes.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Box plots showing the distribution of ages among patients with lymphoma and inflammation. The box represents the lower and upper quartiles, and the median is marked with a horizontal line inside the box. The whiskers are the 10th and 90th percentiles.
FIGURE 2
FIGURE 2
A lymphoma patient had high diffuse uptake of 18F-FDG in the spleen, liver, and bone marrow but no increased 18F-FDG uptake in the lymph nodes and no enlarged peripheral lymph node. The patient had peritoneal effusion and pericardial effusion. 18F-FDG = 18F-fluorodeoxyglucose.
FIGURE 3
FIGURE 3
Box plots showing the distribution of the maximum SUV ratio of spleen/liver among patients with lymphoma and inflammation. The box represents the lower and upper quartiles, and the median is marked with a horizontal line inside the box. The whiskers are the 10th and 90th percentiles with outlying observations individually plotted by squares outside the whiskers. SUV = standardized uptake value.
FIGURE 4
FIGURE 4
Box plots showing the distribution of the maximum SUV ratio of spleen/bone marrow among patients with lymphoma and inflammation. The box represents the lower and upper quartiles, and the median is marked with a horizontal line inside the box. The whiskers are the 10th and 90th percentiles with outlying observations individually plotted by squares outside the whiskers. SUV = standardized uptake value.
FIGURE 5
FIGURE 5
Box plots showing distribution of the maximum SUV ratio of liver/bone marrow among patients with lymphoma and inflammation. The box represents the lower and upper quartiles, and the median is marked with a horizontal line inside the box. The whiskers are the 10th and 90th percentiles with outlying observations individually plotted by squares outside the whiskers. SUV = standardized uptake value.
FIGURE 6
FIGURE 6
Box plots showing distribution of the spleen size among patients with lymphoma and inflammation. The box represents the lower and upper quartiles, and the median is marked with a horizontal line inside the box. The whiskers are the 10th and 90th percentiles.
FIGURE 7
FIGURE 7
An inflammation patient had high diffuse uptake of 18F-FDG in the spleen, liver, and bone marrow but no increased 18F-FDG uptake in the lymph nodes and no enlarged peripheral lymph node. 18F-FDG = 18F-fluorodeoxyglucose.

References

    1. Liu Y. Clinical significance of diffusely increased splenic uptake on FDG-PET. Nucl Med Commun 2009; 30:763–769.
    1. Herrinton LJ, Liu L, Abramson O, et al. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. Pharmacoepidemiol Drug Saf 2012; 21:49–52.
    1. Even-Sapir E, Lievshitz G, Perry C, et al. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with non-Hodgkin lymphoma and Hodgkin's disease. Radiol Clin North Am 2007; 45:697–709.
    1. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology 2004; 232:823–829.
    1. Kraal G. Cells in the marginal zone of the spleen. Int Rev Cytol 1992; 132:31–73.
    1. De Porto AP, Lammers AJ, Bennink RJ, et al. Assessment of splenic function. Eur J Clin Microbiol Infect Dis 2010; 29:1465–1473.
    1. Paik JY, Lee KH, Choe YS, et al. Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med 2004; 45:124–128.
    1. Rutherford SC, Andemariam B, Philips SM, et al. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leuk Lymphoma 2008; 49:719–726.
    1. Sugawara Y, Fisher SJ, Zasadny KR, et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998; 16:173–180.
    1. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429–433.
    1. Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 2005; 43:121–134.
    1. Benseler V, Schlitt HJ. The liver as an immunological organ. Z Gastroenterol 2011; 49:54–62.
    1. Kotzerke J, Guhlmann A, Moog F, et al. Role of attenuation correction for fluorine-18-fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med 1999; 26:31–38.
    1. Meier JM, Alavi A, Iruvuri S, et al. Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Semin Nucl Med 2007; 37:154–172.
    1. Rini J, Manalili EY, Hoffman MA, et al. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 2002; 27:572–577.
    1. Chen YK, Yeh CL, Tsui CC, et al. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med 2011; 36:553–559.
    1. Bangerter M, Moog F, Buchmann I, et al. Whole body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9:1117–1122.
    1. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. J Clin Oncol 1989; 7:1630–1636.
    1. Pakos EE, Fotopoulos AD, Ioannidis JP. 18FFDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005; 46:958–963.
    1. Pelosi E, Penna D, Douroukas A, et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging 2011; 55:469–475.
    1. Fishman EK, Kuhlman JE, Jones RJ. CT of lymphoma: spectrum of disease. RadioGraphics 1991; 11:647–669.
    1. Castellino RA. Hodgkin's disease: practical concepts for the diagnostic radiologists. Radiology 1986; 159:305–310.
    1. Partridge S, Timothy A, O’Doherty MJ, et al. 2-Fluorine-18-fluoro-2-deoxy-d glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11:1273–1279.
    1. Skovsgaard T, Brinckmeyer LM, Vesterager L, et al. The liver in Hodgkin's disease—II. Histopathologic findings. Eur J Cancer Clin Oncol 1982; 18:429–435.
    1. Castellino RA. Imaging techniques for staging abdominal Hodgkin's disease. Cancer Treat Rep 1982; 66:697–700.
    1. Ahmann DL, Kiely JM, Harrison EG, Jr, et al. Malignant lymphoma of the spleen. A review of 49 cases in which the diagnosis was made at splenectomy. Cancer 1966; 19:461–469.
    1. Warshauer DM. Splenic sarcoidosis. Semin Ultrasound CT MR 2007; 28:21–27.
    1. Chapman SJ, Davies RJ. Recent advances in parapneumonic effusion and empyema. Curr Opin Pulm Med 2004; 10:299–304.
    1. Rueffer U, Sieber M, Josting A, et al. Prognostic factors for subdiaphragmatic involvement in clinical stage I–II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG. Ann Oncol 1999; 10:1343–1348.
    1. Macon WR, Levy NB, Kurtin PJ, et al. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 2001; 25:285–296.
    1. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88:4265–4274.
    1. Salhany KE, Feldman M, Peritt D, et al. Cytotoxic T-lymphocyte differentiation and cytogenetic alterations in gammadelta hepatosplenic T-cell lymphoma and posttransplant lymphoproliferative disorders. Blood 1997; 89:3490–3491.
    1. Roelandt PR, Maertens J, Vandenberghe P, et al. Hepatosplenic gam-madelta T-cell lymphoma after liver transplantation: report of the first 2 cases and review of the literature. Liver Transplant 2009; 15:686–692.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit